Prekyba Pfizer Inc - PFE CFD
Pridėti prie mėgstamų- Santrauka
- Istoriniai duomenys
- Įvykiai
- Pajamų ataskaita
- Balansas
- Pinigų srautai
- Nuosavybė
Prekybos sąlygos
| Skirtumas | 0.16 | ||||||||
|
Ilgos pozicijos nakties mokestis
Long position overnight fee
Eiti į platformą | -0.006402% | ||||||||
|
Trumpos pozicijos nakties mokestis
Short position overnight fee
Eiti į platformą | -0.005927% | ||||||||
| Nakties mokesčio laikas | 22:00 (UTC) | ||||||||
| Mažiausias parduodamas kiekis | 1 | ||||||||
| Valiuta | USD | ||||||||
| Marža | 20% | ||||||||
| Akcijų birža | United States of America | ||||||||
| Prekybos mokesčiai | 0% |
*Information provided by Capital.com
Pfizer Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Pagrindiniai statistiniai duomenys
| Ankstesnis uždarymas* | 44.18 |
| Atviras* | 44.18 |
| 1 metų pokytis* | -17.5% |
| Dienos intervalas* | 43.88 - 44.31 |
| 52 savaičių intervalas | 41.45-56.32 |
| Vidutinė apimtis (10 dienų) | 28.04M |
| Vidutinė apimtis (3 mėn.) | 449.46M |
| Rinkos kapitalizacija | 248.89B |
| P/E santykis | 8.10 |
| Neišpirktos akcijos | 5.61B |
| Pajamos | 100.33B |
| EPS | 5.47 |
| Dividendai (pajamingumas %) | 3.69869 |
| Beta | 0.61 |
| Kito pelno data | May 1, 2023 |
Visus duomenis pateikė Refinitiv, išskyrus žvaigždute pažymėtus duomenis, kurie yra Capital.com pateikti *duomenys
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Uždarymas | Change | Change (%) | Atidarymas | High | Low |
|---|---|---|---|---|---|---|
| Feb 3, 2023 | 44.27 | 0.00 | 0.00% | 44.27 | 44.33 | 44.27 |
| Feb 2, 2023 | 44.26 | 0.25 | 0.57% | 44.01 | 44.44 | 43.47 |
| Feb 1, 2023 | 44.01 | -0.20 | -0.45% | 44.21 | 44.24 | 43.39 |
| Jan 31, 2023 | 44.21 | 0.72 | 1.66% | 43.49 | 44.25 | 41.79 |
| Jan 30, 2023 | 43.49 | -0.11 | -0.25% | 43.60 | 44.11 | 43.29 |
| Jan 27, 2023 | 43.71 | -0.43 | -0.97% | 44.14 | 44.32 | 43.45 |
| Jan 26, 2023 | 44.14 | -1.00 | -2.22% | 45.14 | 45.19 | 43.60 |
| Jan 25, 2023 | 45.01 | 0.31 | 0.69% | 44.70 | 45.15 | 44.49 |
| Jan 24, 2023 | 44.71 | -0.26 | -0.58% | 44.97 | 45.01 | 43.99 |
| Jan 23, 2023 | 44.97 | -0.11 | -0.24% | 45.08 | 45.29 | 44.57 |
| Jan 20, 2023 | 44.99 | 0.00 | 0.00% | 44.99 | 45.41 | 44.70 |
| Jan 19, 2023 | 44.98 | 0.00 | 0.00% | 44.98 | 45.24 | 44.52 |
| Jan 18, 2023 | 45.04 | -1.00 | -2.17% | 46.04 | 46.28 | 44.92 |
| Jan 17, 2023 | 46.04 | -1.07 | -2.27% | 47.11 | 47.29 | 45.70 |
| Jan 13, 2023 | 47.72 | 0.10 | 0.21% | 47.62 | 48.13 | 46.99 |
| Jan 12, 2023 | 47.62 | 0.26 | 0.55% | 47.36 | 47.71 | 46.56 |
| Jan 11, 2023 | 47.36 | -0.28 | -0.59% | 47.64 | 47.80 | 46.81 |
| Jan 10, 2023 | 47.64 | -0.72 | -1.49% | 48.36 | 48.59 | 47.36 |
| Jan 9, 2023 | 48.39 | -2.28 | -4.50% | 50.67 | 50.70 | 48.27 |
| Jan 6, 2023 | 50.89 | 1.31 | 2.64% | 49.58 | 51.56 | 49.54 |
Pfizer Inc Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, February 6, 2023 | ||
| Time (UTC) 13:30 | Country US
| Event Q4 2022 Pfizer Inc Earnings Release Q4 2022 Pfizer Inc Earnings ReleaseForecast -Previous - |
| Friday, April 28, 2023 | ||
| Time (UTC) 13:00 | Country US
| Event Pfizer Inc Annual Shareholders Meeting Pfizer Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, May 1, 2023 | ||
| Time (UTC) 12:30 | Country US
| Event Q1 2023 Pfizer Inc Earnings Release Q1 2023 Pfizer Inc Earnings ReleaseForecast -Previous - |
| Thursday, May 18, 2023 | ||
| Time (UTC) 10:59 | Country IN
| Event Q4 2023 Pfizer Ltd Earnings Release Q4 2023 Pfizer Ltd Earnings ReleaseForecast -Previous - |
- Metinis
- Kas ketvirtį
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Visos pajamos | 52824 | 52546 | 40825 | 41172 | 41651 | 81288 |
| Pajamos | 52824 | 52546 | 40825 | 41172 | 41651 | 81288 |
| Bendros pajamos, iš viso | 11925 | 10838 | 8872 | 8043 | 8405 | 30688 |
| Pajamos | 40899 | 41708 | 31953 | 33129 | 33246 | 50600 |
| Pajamų sąnaudos, iš viso | 43820 | 39557 | 36763 | 28841 | 33839 | 57636 |
| Pardavimas / Bendrosios / administravimo išlaidos, iš viso | 14837 | 14784 | 12419 | 12485 | 11402 | 12256 |
| Tyrimai ir plėtra | 7872 | 7657 | 7713 | 7731 | 9340 | 11582 |
| Depreciation / Amortization | 4056 | 4758 | 4736 | 4462 | 3348 | 3700 |
| Neįprastos išlaidos (pajamos) | 6058 | 2594 | 4675 | -2914 | 2619 | 3897 |
| Other Operating Expenses, Total | -928 | -1074 | -1652 | -966 | -1275 | -4487 |
| Veiklos pajamos | 9004 | 12989 | 4062 | 12331 | 7812 | 23652 |
| Palūkanų pajamos (išlaidos), grynosios ne veiklos pajamos | -824 | -972 | -538 | -877 | -538 | 560 |
| Gain (Loss) on Sale of Assets | 171 | 288 | 71 | 32 | -237 | 99 |
| Grynosios pajamos prieš mokesčius | 8351 | 12305 | 3594 | 11485 | 7036 | 24311 |
| Grynosios pajamos po mokesčių | 7228 | 11954 | 3264 | 10545 | 6666 | 22459 |
| Mažumos palūkanos | -31 | -47 | -36 | -29 | -36 | -45 |
| Grynosios pajamos prieš papildomas. Prekės | 7197 | 11907 | 3228 | 10516 | 6630 | 22414 |
| Iš viso nepaprastųjų prekių | 17 | 9402 | 7924 | 5757 | 2529 | -434 |
| Grynosios pajamos | 7214 | 21309 | 11152 | 16273 | 9159 | 21980 |
| Total Adjustments to Net Income | 0 | -2 | 0 | -1 | 0 | -1 |
| Pajamos, kurias galima gauti bendrai, išskyrus papildomas pajamas. Prekės | 7197 | 11905 | 3228 | 10515 | 6630 | 22413 |
| Pajamos, kurias galima gauti bendrai, įskaitant papildomas pajamas. Prekės | 7214 | 21307 | 11152 | 16272 | 9159 | 21979 |
| Skiedžiamas grynasis pelnas | 7214 | 21307 | 11152 | 16272 | 9159 | 21979 |
| Skiedžiamas svertinis vidutinis akcijų skaičius | 6159 | 6058 | 5977 | 5675 | 5632 | 5708 |
| Skiedžiamas pelnas už akcijas, neįskaitant ypatingų prekių | 1.16853 | 1.96517 | 0.54007 | 1.85286 | 1.1772 | 3.92659 |
| Dividends per Share - Common Stock Primary Issue | 1.2 | 1.28 | 1.36 | 1.44 | 1.52 | 1.56 |
| Skiedžiamas normalizuotas pelnas, gautas iš pelno | 2.10748 | 2.31727 | 1.04885 | 1.22837 | 1.45366 | 4.09303 |
| Kita, pajamos | -1 | -1 | -1 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Visos pajamos | 14516 | 18977 | 24094 | 23635 | 25661 |
| Pajamos | 14516 | 18977 | 24094 | 23635 | 25661 |
| Bendros pajamos, iš viso | 4187 | 6986 | 9925 | 9611 | 10010 |
| Pajamos | 10329 | 11991 | 14169 | 14024 | 15651 |
| Pajamų sąnaudos, iš viso | 8989 | 13063 | 16447 | 19059 | 15788 |
| Pardavimas / Bendrosios / administravimo išlaidos, iš viso | 2901 | 2794 | 2733 | 4069 | 2691 |
| Tyrimai ir plėtra | 2010 | 2270 | 2738 | 4565 | 2655 |
| Depreciation / Amortization | 858 | 931 | 981 | 916 | 835 |
| Neįprastos išlaidos (pajamos) | -25 | 754 | 1613 | 1283 | 122 |
| Other Operating Expenses, Total | -942 | -672 | -1543 | -1385 | -525 |
| Veiklos pajamos | 5527 | 5914 | 7647 | 4576 | 9873 |
| Palūkanų pajamos (išlaidos), grynosios ne veiklos pajamos | 127 | 637 | 190 | -394 | -823 |
| Gain (Loss) on Sale of Assets | 39 | 58 | 1 | 0 | 1 |
| Kita, pajamos | -1 | -2 | 1 | -1 | |
| Grynosios pajamos prieš mokesčius | 5692 | 6609 | 7836 | 4183 | 9050 |
| Grynosios pajamos po mokesčių | 4884 | 5566 | 8167 | 3849 | 7878 |
| Mažumos palūkanos | -9 | -26 | -12 | 2 | -6 |
| Grynosios pajamos prieš papildomas. Prekės | 4875 | 5540 | 8155 | 3851 | 7872 |
| Iš viso nepaprastųjų prekių | 1 | 24 | -9 | -458 | -9 |
| Grynosios pajamos | 4876 | 5564 | 8146 | 3393 | 7863 |
| Total Adjustments to Net Income | 1 | -1 | 1 | ||
| Pajamos, kurias galima gauti bendrai, išskyrus papildomas pajamas. Prekės | 4876 | 5539 | 8155 | 3851 | 7873 |
| Pajamos, kurias galima gauti bendrai, įskaitant papildomas pajamas. Prekės | 4877 | 5563 | 8146 | 3393 | 7864 |
| Skiedžiamas grynasis pelnas | 4877 | 5563 | 8146 | 3393 | 7864 |
| Skiedžiamas svertinis vidutinis akcijų skaičius | 5662 | 5678 | 5725 | 5768 | 5758 |
| Skiedžiamas pelnas už akcijas, neįskaitant ypatingų prekių | 0.86118 | 0.97552 | 1.42445 | 0.66765 | 1.36732 |
| Dividends per Share - Common Stock Primary Issue | 0.39 | 0.39 | 0.39 | 0.39 | 0.4 |
| Skiedžiamas normalizuotas pelnas, gautas iš pelno | 0.82179 | 1.06851 | 1.40629 | 0.74896 | 1.31052 |
- Metinis
- Kas ketvirtį
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Trumpalaikis turtas iš viso | 38949 | 41141 | 49926 | 32803 | 35067 | 59693 |
| Pinigai ir trumpalaikės investicijos | 17850 | 19992 | 18833 | 9646 | 12221 | 31069 |
| Pinigai ir ekvivalentai | 2595 | 1342 | 1139 | 1121 | 1784 | 1944 |
| Trumpalaikės investicijos | 15255 | 18650 | 17694 | 8525 | 10437 | 29125 |
| Gautinos sumos, iš viso, grynąja verte | 8225 | 8221 | 8025 | 6772 | 7930 | 11479 |
| Accounts Receivable - Trade, Net | 8225 | 8221 | 8025 | 6772 | 7930 | 11479 |
| Total Inventory | 6783 | 7578 | 7508 | 7068 | 8046 | 9059 |
| Other Current Assets, Total | 6091 | 5350 | 15560 | 9317 | 6870 | 8086 |
| Total Assets | 171615 | 171797 | 159422 | 167594 | 154229 | 181476 |
| Property/Plant/Equipment, Total - Net | 13318 | 13865 | 13385 | 14258 | 15293 | 17721 |
| Property/Plant/Equipment, Total - Gross | 28125 | 30037 | 29977 | 29248 | 30104 | 32794 |
| Accumulated Depreciation, Total | -14807 | -16172 | -16591 | -14990 | -14812 | -15074 |
| Goodwill, Net | 54449 | 55952 | 53411 | 48202 | 49577 | 49208 |
| Intangibles, Net | 52648 | 48741 | 35211 | 33936 | 28471 | 25146 |
| Long Term Investments | 7116 | 7015 | 2767 | 20147 | 20262 | 21526 |
| Other Long Term Assets, Total | 5135 | 5083 | 4722 | 18248 | 5559 | 8182 |
| Total Current Liabilities | 31115 | 30427 | 31858 | 37304 | 25920 | 42671 |
| Accounts Payable | 4536 | 4656 | 4674 | 3887 | 4309 | 5578 |
| Accrued Expenses | 2487 | 2196 | 2397 | 2659 | 3379 | 3781 |
| Notes Payable/Short Term Debt | 6463 | 6407 | 4055 | 14733 | 701 | 605 |
| Current Port. of LT Debt/Capital Leases | 4225 | 3546 | 4776 | 1462 | 2002 | 1636 |
| Other Current Liabilities, Total | 13404 | 13622 | 15956 | 14563 | 15529 | 31071 |
| Total Liabilities | 112071 | 100489 | 96015 | 104450 | 90991 | 104276 |
| Total Long Term Debt | 31398 | 33538 | 32909 | 35955 | 37133 | 36195 |
| Long Term Debt | 31398 | 33538 | 32909 | 35955 | 37133 | 36195 |
| Deferred Income Tax | 30753 | 3900 | 3700 | 5652 | 4063 | 349 |
| Minority Interest | 296 | 348 | 351 | 303 | 235 | 262 |
| Other Liabilities, Total | 18509 | 32276 | 27197 | 25236 | 23640 | 24799 |
| Total Equity | 59544 | 71308 | 63407 | 63144 | 63238 | 77200 |
| Preferred Stock - Non Redeemable, Net | 24 | 21 | 19 | 17 | 0 | |
| Common Stock | 461 | 464 | 467 | 468 | 470 | 473 |
| Additional Paid-In Capital | 82685 | 84278 | 86253 | 87428 | 88674 | 90591 |
| Retained Earnings (Accumulated Deficit) | 71774 | 85291 | 89554 | 97670 | 96770 | 103394 |
| Treasury Stock - Common | -84364 | -89425 | -101610 | -110801 | -110988 | -111361 |
| Unrealized Gain (Loss) | -131 | 401 | -68 | -35 | 116 | -220 |
| Other Equity, Total | -10905 | -9722 | -11208 | -11603 | -11804 | -5677 |
| Total Liabilities & Shareholders’ Equity | 171615 | 171797 | 159422 | 167594 | 154229 | 181476 |
| Total Common Shares Outstanding | 6070 | 5979 | 5717 | 5534 | 5567 | 5620 |
| Total Preferred Shares Outstanding | 0.0006 | 0.00052 | 0.00048 | 0.00043 | 0 | 0 |
| Apr 2021 | Jul 2021 | Oct 2021 | Dec 2021 | Apr 2022 | |
|---|---|---|---|---|---|
| Trumpalaikis turtas iš viso | 39533 | 48814 | 57900 | 59693 | 54420 |
| Pinigai ir trumpalaikės investicijos | 13667 | 21700 | 29696 | 31069 | 23897 |
| Pinigai ir ekvivalentai | 1768 | 2372 | 1966 | 1944 | 2470 |
| Trumpalaikės investicijos | 11899 | 19328 | 27730 | 29125 | 21427 |
| Gautinos sumos, iš viso, grynąja verte | 9864 | 10587 | 11897 | 11479 | 13225 |
| Accounts Receivable - Trade, Net | 9864 | 10587 | 11897 | 11479 | 13225 |
| Total Inventory | 8493 | 8948 | 8640 | 9059 | 9979 |
| Other Current Assets, Total | 7509 | 7579 | 7667 | 8086 | 7319 |
| Total Assets | 158818 | 169920 | 179188 | 181476 | 183841 |
| Property/Plant/Equipment, Total - Net | 14011 | 14224 | 14436 | 14882 | 15109 |
| Property/Plant/Equipment, Total - Gross | 29116 | 29552 | 29839 | 29955 | 30467 |
| Accumulated Depreciation, Total | -15105 | -15328 | -15403 | -15074 | -15358 |
| Goodwill, Net | 49791 | 49867 | 49489 | 49208 | 50211 |
| Intangibles, Net | 27974 | 27323 | 26306 | 25146 | 29816 |
| Long Term Investments | 20228 | 20942 | 21597 | 21526 | 20737 |
| Other Long Term Assets, Total | 7281 | 8750 | 9460 | 11021 | 13548 |
| Total Current Liabilities | 26652 | 35664 | 41803 | 42671 | 39268 |
| Accounts Payable | 4064 | 4327 | 4698 | 5578 | 5506 |
| Accrued Expenses | 1985 | 2015 | 2571 | 3332 | 2249 |
| Notes Payable/Short Term Debt | 676 | 201 | 966 | 605 | 385 |
| Current Port. of LT Debt/Capital Leases | 3676 | 3687 | 2663 | 1636 | 260 |
| Other Current Liabilities, Total | 16251 | 25434 | 30905 | 31520 | 30868 |
| Total Liabilities | 90198 | 99878 | 103496 | 104276 | 101417 |
| Total Long Term Debt | 35347 | 35354 | 36250 | 36195 | 35656 |
| Long Term Debt | 35347 | 35354 | 36250 | 36195 | 35656 |
| Deferred Income Tax | 4355 | 4161 | 328 | 349 | 655 |
| Minority Interest | 245 | 273 | 275 | 262 | 261 |
| Other Liabilities, Total | 23599 | 24426 | 24840 | 24799 | 25577 |
| Total Equity | 68620 | 70042 | 75692 | 77200 | 82424 |
| Common Stock | 472 | 472 | 473 | 473 | 476 |
| Additional Paid-In Capital | 89002 | 89336 | 89973 | 90591 | 90844 |
| Retained Earnings (Accumulated Deficit) | 95158 | 96346 | 102252 | 103394 | 111193 |
| Treasury Stock - Common | -111349 | -111356 | -111359 | -111361 | -113931 |
| Unrealized Gain (Loss) | -26 | 79 | -146 | -220 | -133 |
| Other Equity, Total | -4637 | -4835 | -5501 | -5677 | -6025 |
| Total Liabilities & Shareholders’ Equity | 158818 | 169920 | 179188 | 181476 | 183841 |
| Total Common Shares Outstanding | 5594 | 5599 | 5611 | 5620 | 5591 |
| Total Preferred Shares Outstanding | 0 |
- Metinis
- Kas ketvirtį
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Grynosios pajamos / pradinė eilutė | 7246 | 21355 | 11188 | 16302 | 9652 | 22025 |
| Pagrindinės veiklos pinigai | 16193 | 16802 | 15827 | 12587 | 14403 | 32580 |
| Pagrindinės veiklos pinigai | 5757 | 6269 | 6384 | 6010 | 4777 | 5191 |
| Deferred Taxes | -700 | -2410 | -2205 | 614 | -1468 | -4293 |
| Nepiniginės prekės | 3791 | -9748 | 1387 | -6307 | 1717 | -3147 |
| Cash Taxes Paid | 2521 | 2489 | 3655 | 3664 | 3153 | 7427 |
| Sumokėtos palūkanos grynaisiais pinigais | 1451 | 1518 | 1311 | 1587 | 1641 | 1467 |
| Apyvartinio kapitalo pokyčiai | 99 | 1336 | -927 | -4032 | -275 | 12804 |
| Investicinės veiklos pinigai | -7791 | -4740 | 4525 | -3945 | -4271 | -22546 |
| Kapitalo išlaidos | -1999 | -2217 | -2196 | -2594 | -2791 | -2711 |
| Kiti investiciniai pinigų srautų iš prekių, iš viso | -5792 | -2523 | 6721 | -1351 | -1480 | -19835 |
| Finansinės veiklos pinigai | -9228 | -13350 | -20441 | -8485 | -9649 | -9816 |
| Finansavimo pinigų srautų prekės | -536 | -612 | -589 | -735 | 11121 | 16 |
| Total Cash Dividends Paid | -7317 | -7659 | -7978 | -8043 | -8440 | -8729 |
| Akcijų išleidimas (išpirkimas), grynasis | -3981 | -4138 | -10939 | -8471 | 425 | 0 |
| Skolos išleidimas (padengimas), grynasis | 2606 | -941 | -935 | 8764 | -12755 | -1103 |
| Užsienio valiutos keitimo įtaka | -215 | 53 | -116 | -32 | -8 | -59 |
| Grynasis pinigų pokytis | -1041 | -1235 | -205 | 125 | 475 | 159 |
| Apr 2021 | Jul 2021 | Oct 2021 | Dec 2021 | Apr 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 4886 | 10475 | 18633 | 22025 | 7870 |
| Cash From Operating Activities | 4539 | 15836 | 26666 | 32580 | 6541 |
| Cash From Operating Activities | 1226 | 2554 | 3914 | 5191 | 1187 |
| Deferred Taxes | 199 | -3702 | -4293 | -2321 | |
| Non-Cash Items | -446 | -1590 | -2997 | -3147 | 537 |
| Cash Taxes Paid | 394 | 2188 | 2943 | 7427 | 354 |
| Cash Interest Paid | 445 | 798 | 1205 | 1467 | 453 |
| Changes in Working Capital | -1326 | 4397 | 10818 | 12804 | -732 |
| Cash From Investing Activities | -1747 | -9884 | -19960 | -22546 | 567 |
| Capital Expenditures | -554 | -1094 | -1718 | -2711 | -643 |
| Other Investing Cash Flow Items, Total | -1193 | -8790 | -18242 | -19835 | 1210 |
| Cash From Financing Activities | -2807 | -5364 | -6465 | -9816 | -6578 |
| Financing Cash Flow Items | -610 | -510 | -185 | 16 | -500 |
| Total Cash Dividends Paid | -2172 | -4355 | -6540 | -8729 | -2249 |
| Issuance (Retirement) of Debt, Net | -25 | -499 | 260 | -1103 | -1829 |
| Foreign Exchange Effects | 0 | 5 | -32 | -59 | -1 |
| Net Change in Cash | -15 | 593 | 209 | 159 | 529 |
| Issuance (Retirement) of Stock, Net | 0 | -2000 |
| Investuotojo pavadinimas | Investuotojo tipas | Apyvartoje esantis procentas | Turimos akcijos | Turimų akcijų pokytis | Turėjimo data | Apyvartos vertinimas |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.7471 | 491001204 | 5107541 | 2022-09-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.1238 | 287612741 | 395713 | 2022-09-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.0984 | 286187374 | 1836743 | 2022-09-30 | LOW |
| Capital World Investors | Investment Advisor | 4.4332 | 248850529 | -1276218 | 2022-09-30 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 3.7567 | 210874152 | -8297495 | 2022-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.9675 | 110442140 | 1859302 | 2022-09-30 | LOW |
| Charles Schwab Investment Management, Inc. | Investment Advisor | 1.2492 | 70123906 | 6001894 | 2022-09-30 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.0112 | 56763604 | 200794 | 2021-12-31 | LOW |
| Capital International Investors | Investment Advisor | 0.9856 | 55323878 | 5892896 | 2022-09-30 | LOW |
| State Farm Insurance Companies | Insurance Company | 0.9543 | 53568997 | 0 | 2022-09-30 | LOW |
| BofA Global Research (US) | Research Firm | 0.803 | 45074753 | -582392 | 2022-09-30 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7631 | 42832953 | -453753 | 2022-09-30 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7449 | 41814509 | -977163 | 2022-09-30 | LOW |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.7363 | 41330356 | 393541 | 2022-09-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.7347 | 41242414 | 1009399 | 2022-09-30 | LOW |
| MFS Investment Management | Investment Advisor/Hedge Fund | 0.7287 | 40906577 | -874608 | 2022-09-30 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 0.6492 | 36441408 | 1403401 | 2022-09-30 | LOW |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.632 | 35478928 | -2969100 | 2022-09-30 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 0.5195 | 29162770 | -5775440 | 2022-09-30 | LOW |
| Mellon Investments Corporation | Investment Advisor/Hedge Fund | 0.5151 | 28915413 | -87396 | 2022-09-30 | LOW |
Kodėl Capital.com? Mūsų skaičiai kalba už save.
Capital.com Group +485000+
Prekeiviai
65000+
Aktyvūs klientai kas mėnesį
$48000000+
Mėnesio investicijų apimtis
$28000000+
Išbandykite dabar Atsiimama kas mėnesį
Prekybos skaičiuoklė
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Sandorio komisiniai mokesčiai
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Svertas
20:1
- 20
- 100
- 500
- 1000
- 10000
Investavimas
Sandorio dydis (finansinis svertas x investicija):
Atidarymas
Uždarymas
Trumpoji Ilgoji
Pfizer Company profile
Apie Pfizer Inc
"Pfizer Inc." (toliau - "Pfizer") yra moksliniais tyrimais pagrįsta pasaulinė biofarmacijos bendrovė. Bendrovė užsiima biofarmacinių produktų atradimu, kūrimu, gamyba, rinkodara, pardavimu ir platinimu. Jos pasaulinį portfelį sudaro vaistai ir vakcinos. Bendrovė siūlo gastroenterologijos, dermatologijos ir kardiologijos sričių vaistinius preparatus, įskaitant etrasimodą, geriamąjį selektyvų sfingozino 1-fosfato (S1P) receptorių moduliatorių, kuriamą įvairioms imunouždegiminėms ligoms, įskaitant opinį kolitą, Krono ligą, atopinį dermatitą, eozinofilinį ezofagitą ir alopeciją areatą, gydyti. Bendrovė dirba įvairiose rinkose, siekdama kurti sveikatingumo, prevencijos, gydymo ir gydymo priemones. Ji bendradarbiauja su sveikatos priežiūros paslaugų teikėjais, vyriausybėmis ir vietos bendruomenėmis, siekdama remti ir užtikrinti sveikatos priežiūros paslaugų prieinamumą. Bendrovės vaistai ir vakcinos sukuria vertę sveikatos priežiūros paslaugų teikėjams ir pacientams, gydant ligas, gerinant sveikatą, sveikatingumą.
| Industry: | Pharmaceuticals (NEC) |
235 E 42nd St
NEW YORK
NEW YORK 10017
US
Pajamų ataskaita
- Annual
- Quarterly
Žmonės taip pat žiūri
Vis dar ieškote brokerio kuriuo galėtumėte pasitikėti?
Prisijunkite prie 485 000+ prekeivių visame pasaulyje, kurie pasirinko prekybą su Capital.com